Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Unique Immune Signatures Distinguish Rare Autoimmune Condition from Multiple Sclerosis

By LabMedica International staff writers
Posted on 25 Nov 2025

Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) is a rare autoimmune disorder in which the immune system attacks the myelin sheath in the central nervous system. More...

Although symptoms can resemble multiple sclerosis (MS), including inflammation of the optic nerve and spinal cord, the underlying biology appears fundamentally different. These differences may explain why standard MS treatments often fail to show benefit in MOGAD. A new international study now reveals key immune distinctions that could guide more precise therapies.

In the study led by the University of Zurich (Zurich, Switzerland), an international team of researchers performed extensive immune-cell profiling to characterize MOGAD, comparing patients with individuals diagnosed with MS and with healthy controls. Using deep immunophenotyping techniques, the investigators analyzed natural killer cells, T cells, B cells, and other immune subsets to capture a detailed picture of disease biology. Their objective was to uncover immune mechanisms that distinguish MOGAD from other neuroinflammatory disorders, given that conventional MS therapies frequently show limited effectiveness in this condition.

The study revealed pronounced differences across multiple immune-cell populations. Distinct patterns involving NK cells, T cells, and B cells emerged consistently in MOGAD patients when compared to MS and healthy individuals. These results, published in Science Translational Medicine, demonstrate that MOGAD carries a unique immunological signature that clearly separates it from MS. The dataset provides one of the most comprehensive immune maps for this rare condition to date.

These findings strengthen the view that MOGAD is a standalone disease entity rather than a variant of MS. By identifying which immune pathways behave differently, the research offers critical clues for designing targeted, disease-specific therapies. Importantly, the immune-cell signatures generated in this work create a scientific foundation for more personalized approaches in neuroinflammatory disease management. Before reaching clinical practice, the mechanistic hypotheses derived from these profiles must undergo rigorous testing in future clinical studies.

“These findings support MOGAD as its own disease entity, distinct from other neuroinflammatory conditions such as MS,” said researcher Prof. Anne-Katrin Pröbstel. “Importantly, this work lays the foundation for hypothesis-driven research aimed at understanding MOGAD’s unique immunopathology and developing targeted therapies.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.